A Phase 2 Study of Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 26 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 19 May 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 15 Aug 2022 Planned End Date changed from 30 Apr 2022 to 30 Dec 2022.